Available EU DMF/CEP
EU DMF
CEP
API Status
Commercial
Pipeline
Therapeutic Category
Alimentary tract & metabolism
Anti-infectives for systemic use
Antipyretic, analgesic and anti-inflammatory
Antineoplastic & immunomodulating agents
Blood & blood forming organs
Cardiovascular system
Genito-urinary system & sex hormones
Injectable forms
Musculo-skeletal system
Nervous system
Opthalmological preparations
Respiratory system
Available US DMF
US DMF
Available Japanese/Chinese DMF
Japanese DMF
Chinese DMF
Korean DMF

Safinamide methanesulfonate*

CAS No.

202825-46-5

Innovator/marketer

Xadago

Polymorphic form

Crystalline anhydrous modification A1

Therapeutic Area

Nervous system

Status

Pipeline

EU DMF readiness

Q1 2018

US DMF readiness

Q1 2018

Drug description:

Safinamide is an alpha-aminoamide derivative acts as add-on therapy to dopamine agonists or levodopa.
Safinamide is indicated in the treatment of idiopathic Parkinson's disease (PD) or for mid-to late-stage fluctuating patients as add-on therapy to a stable dose of Levodopa (L-dopa) alone or in combination with other PD medicinal products.
It is formulated as film-coated tablets for oral route of administration.

Mechanism of action:

Safinamide has a dual mechanism of action based on the enhancement of the dopaminergic function (through potent reversible inhibition of MAO-B and of dopamine uptake) and inhibition of excessive release of glutamate.

* product not covered by a compound patent in the territory of Poland

DISCLAIMER
The above product is presented solely for informational purposes and does not constitute an offer in any sense. Products under patent (SPC) protection in Poland and/or other countries are not offered until expiration of the corresponding IP right.

OK